开发和验证一种机器学习模型,用于预测与口服糖尿病药物的药物相互作用
Quang-Hien Kha1, Ngan Thi Kim Nguyen2, Nguyen Quoc Khanh Le3
1International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; AIBioMed Research Group, Taipei Medical University, Taipei 110, Taiwan.
Methods (San Diego, Calif.)
|November 3, 2024
概括
这项研究引入了一种机器学习模型,用于预测危险的药物相互作用 (DDI),特别用于口服糖尿病药物. 该工具通过识别复杂药物治疗方案中的潜在风险来提高患者的安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
- 人工智能在医学中的应用
背景情况:
- 糖尿病管理是复杂的,通常涉及多种药物.
- 药物相互作用 (DDI) 在患有并发症的患者中存在重大风险.
- 目前用于DDI预测的机器学习 (ML) 模型缺乏针对口服糖尿病药物的特异性和可解释性.
研究的目的:
- 开发一种基于ML的新框架,用于预测涉及口服糖尿病药物的DDI.
- 提高DDI预测模型的可解释性和临床相关性.
- 为在糖尿病管理中提供一个更安全的处方实践工具.
主要方法:
- 利用简化分子输入线输入系统 (SMILES) 进行口服糖尿病药物的结构编码.
- 用LASSO开发了一个XGBoost分类模型用于特征选择.
- 采用了SHAP分析来分析模型的可解释性.
- 在42种口服糖尿病药物和来自DrugBank的1884种相互作用药物的数据集上训练并验证了模型.
主要成果:
- 在ML模型中,F1得分为0.8182.2.
- 鉴定了606个重要的分子特征,可以预测DDI.
- SHAP分析提供了对原子级相互作用的见解,并提高了模型的透明度.
结论:
- 开发的ML模型准确地预测了口服糖尿病药物的不良DDI.
- 该模型为临床决策和更安全的处方提供了宝贵的见解.
- 一个公开可访问的网络应用程序支持在复杂的多药疗法中进行糖尿病管理.
相关概念视频
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
160
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
160
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
49
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
49
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
60
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
60


